Head-To-Head Comparison: Clever Leaves (NASDAQ:CLVR) vs. Intensity Therapeutics (NASDAQ:INTS)

Intensity Therapeutics (NASDAQ:INTS) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Institutional & Insider Ownership

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 7.6% of Intensity Therapeutics shares are owned by insiders. Comparatively, 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Intensity Therapeutics and Clever Leaves”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61 million	($3.57)	-1.36
Clever Leaves	$17.42 million	0.00	-$17.90 million	($9.66)	-0.00

Intensity Therapeutics has higher earnings, but lower revenue than Clever Leaves. Intensity Therapeutics is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intensity Therapeutics and Clever Leaves’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
Clever Leaves	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Intensity Therapeutics and Clever Leaves, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1	0	3	1	2.80
Clever Leaves	0	0	0	0	0.00

Intensity Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 44.03%. Given Intensity Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than Clever Leaves.

Volatility & Risk

Intensity Therapeutics has a beta of 2.76, meaning that its share price is 176% more volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 3845.81, meaning that its share price is 384,481% more volatile than the S&P 500.

Summary

Clever Leaves beats Intensity Therapeutics on 7 of the 13 factors compared between the two stocks.

About Intensity Therapeutics

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

About Clever Leaves

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.